Somatostatin Analogs

Lanreotide for Neuroendocrine Tumors

11 min read|March 22, 2026

Somatostatin Analogs

65% PFS at 2 years

In the CLARINET trial, 65.1% of patients receiving lanreotide were progression-free at 24 months, compared to 33.0% on placebo, in metastatic enteropancreatic neuroendocrine tumors.

Caplin et al., New England Journal of Medicine, 2014

View as image

Lanreotide is a synthetic octapeptide analog of somatostatin, the endogenous hormone that inhibits growth hormone, insulin, glucagon, and gastric acid secretion. Marketed as Somatuline Depot (US) or Somatuline Autogel (Europe), lanreotide is administered as a deep subcutaneous injection of 120 mg every 28 days. Its FDA approval for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) was based on the CLARINET trial, published in the New England Journal of Medicine in 2014, which demonstrated that lanreotide nearly doubled progression-free survival compared to placebo. This article reviews the CLARINET evidence, long-term extension data, comparison with octreotide, and the biological basis of somatostatin analog therapy in neuroendocrine tumors.

Key Takeaways

The CLARINET trial randomized 204 patients with metastatic G1/G2 enteropancreatic NETs to lanreotide 120mg or placebo every 28 days for 96 weeks; PFS at 24 months was 65.1% vs 33.0% (HR 0.47, P<0.001) (Caplin et al., 2014)
In the CLARINET open-label extension, patients who received continuous lanreotide had median PFS of 32.8 months from extension entry; crossover patients from placebo had 14.0 months (Caplin et al., 2021)
The earlier PROMID trial of octreotide LAR showed similar antiproliferative effects (TTP 14.3 vs 6.0 months; HR 0.34) but in a smaller, midgut-only population (Rinke et al., 2009)
Lanreotide binds preferentially to somatostatin receptor subtype 2 (SSTR2), the most commonly overexpressed receptor on well-differentiated NETs
Most common adverse events were diarrhea (26%) and abdominal pain (14%); no new safety signals in long-term use
Somatostatin analogs are now standard first-line antiproliferative therapy for G1/G2 GEP-NETs in all major guidelines

How Somatostatin Analogs Work Against Tumors

Neuroendocrine tumors arise from cells of the diffuse neuroendocrine system that express somatostatin receptors, particularly SSTR2. Native somatostatin has a half-life of approximately 2 minutes, making it useless as a therapy. Lanreotide and octreotide are synthetic analogs engineered for metabolic stability while retaining receptor binding.

Lanreotide binds primarily to SSTR2, with moderate affinity for SSTR5 and weak affinity for SSTR1, SSTR3, and SSTR4. For a full discussion of these receptor subtypes, see Somatostatin Receptor Subtypes: Why One Peptide Has Five Different Targets.

Deghenghi et al. (2001) demonstrated that lanreotide, octreotide, and vapreotide all share the growth hormone-releasing peptide (GHRP) receptor in the human pituitary gland, in addition to their somatostatin receptor binding.^[1] This dual receptor interaction may contribute to effects beyond simple somatostatin receptor agonism.

The antiproliferative mechanism involves both direct and indirect pathways. Direct effects include cell cycle arrest (primarily G1 arrest), induction of apoptosis, and inhibition of angiogenesis. Indirect effects include suppression of growth factors (IGF-1, VEGF, EGF) and modulation of immune responses. Tumor imaging with 68Ga-DOTATATE PET confirms SSTR2 expression before starting therapy, which is why somatostatin receptor positivity was an entry criterion for CLARINET.

The CLARINET Trial: Definitive Evidence

The CLARINET study (Controlled Study of Lanreotide Antiproliferative Response in Neuroendocrine Tumors) was a phase 3, double-blind, placebo-controlled trial published in the New England Journal of Medicine.^[2]

Study Design

Population: 204 patients with metastatic, well-differentiated or moderately differentiated, nonfunctioning, somatostatin receptor-positive, grade 1 or 2 (Ki-67 <10%) enteropancreatic NETs
Randomization: 1:1 to lanreotide 120 mg deep subcutaneous injection or matching placebo every 28 days
Duration: 96 weeks (approximately 2 years)
Primary endpoint: Progression-free survival (PFS)
Key inclusion criteria: Disease progression not required at entry (patients with stable disease were included)

Results

Lanreotide produced a 53% reduction in the risk of disease progression or death:

Median PFS: Not reached for lanreotide vs 18.0 months for placebo
PFS at 24 months: 65.1% for lanreotide vs 33.0% for placebo
Hazard ratio: 0.47 (95% CI 0.30-0.73; P<0.001)

The treatment effect was consistent across prespecified subgroups, including pancreatic vs intestinal primary, hepatic tumor burden above or below 25%, and prior treatment status. Quality of life scores were similar between groups, meaning that the antiproliferative benefit came without a quality-of-life cost.

Safety Profile

Lanreotide was well-tolerated. The most common adverse events were:

Diarrhea: 26% (vs 9% placebo)
Abdominal pain: 14% (vs 2% placebo)
Cholelithiasis (gallstones): 10% (vs 3% placebo)

Gallstone formation is a class effect of somatostatin analogs, caused by reduced gallbladder motility and bile flow. Most cases were asymptomatic and did not require treatment discontinuation.

What CLARINET Proved

CLARINET was the first trial to demonstrate antiproliferative activity of a somatostatin analog across both intestinal and pancreatic NETs in a single study. Its inclusion of patients with stable disease at entry was controversial but important: it showed that lanreotide prevents progression even in the absence of recent tumor growth, supporting its use as first-line maintenance therapy rather than rescue treatment.

Long-Term Data: CLARINET Open-Label Extension

Patients who completed the 96-week CLARINET core study could enter the open-label extension (OLE), where all patients received lanreotide 120 mg every 28 days.^[3]

For patients who received lanreotide throughout (core + OLE), median PFS from OLE entry was 32.8 months. Patients who had been on placebo in the core study and switched to lanreotide had a median PFS of 14.0 months from OLE entry. This crossover data provides a within-study comparison: patients who started lanreotide earlier had better outcomes than those who switched later, suggesting that early initiation of somatostatin analog therapy may be more effective than waiting for progression.

The safety profile in the OLE was consistent with the core study. No new adverse events emerged with prolonged exposure.

Comparison With Octreotide: PROMID Trial

The PROMID trial, published in the Journal of Clinical Oncology in 2009, was the first randomized evidence for somatostatin analog antiproliferative activity in NETs.^[4]

PROMID randomized 85 patients with metastatic midgut NETs to octreotide LAR 30 mg or placebo monthly. Octreotide prolonged time to tumor progression (14.3 vs 6.0 months; HR 0.34; P=0.000072). The antiproliferative effect was most pronounced in patients with low hepatic tumor burden (tumor load under 10% of liver volume).

Key Differences Between CLARINET and PROMID

Feature	CLARINET (Lanreotide)	PROMID (Octreotide)
Sample size	204	85
Tumor origin	Intestinal + pancreatic	Midgut only
Functional tumors	Excluded	Included
Stable disease at entry	Allowed	Allowed
Ki-67 threshold	<10%	Not specified
PFS HR vs placebo	0.47	0.34
Primary endpoint	PFS	TTP

No head-to-head trial has compared lanreotide to octreotide for antiproliferative efficacy. Current guidelines treat them as interchangeable for this indication. The choice between them in practice often depends on administration convenience: lanreotide is self-injectable as a deep subcutaneous depot; octreotide LAR requires intramuscular injection by a healthcare provider.

Where Lanreotide Fits in NET Treatment

Somatostatin analogs are now the standard first-line antiproliferative therapy for well-differentiated G1/G2 GEP-NETs in ENETS, NCCN, and ESMO guidelines. The treatment algorithm typically proceeds:

Confirm SSTR expression via 68Ga-DOTATATE PET or OctreoScan
First-line: Somatostatin analog (lanreotide or octreotide) for G1/G2 SSTR-positive tumors
Second-line options: Everolimus, peptide receptor radionuclide therapy (PRRT), sunitinib (pancreatic), or temozolomide-based chemotherapy
Monitoring: Chromogranin A levels and periodic imaging

Lanreotide also has established roles in acromegaly (first approved indication) and is under investigation for polycystic liver and kidney disease.

Limitations of the Evidence

G1/G2 only. CLARINET enrolled grade 1 and 2 tumors with Ki-67 under 10%. Whether lanreotide has antiproliferative activity in G3 or high-Ki-67 G2 tumors is not established. These patients are typically treated with chemotherapy or targeted agents.

Nonfunctioning tumors only. CLARINET excluded functioning tumors (those producing hormones causing clinical syndromes). While somatostatin analogs are used for symptom control in functioning NETs, the antiproliferative evidence is specific to nonfunctioning tumors.

No overall survival benefit demonstrated. CLARINET showed PFS benefit but was not powered for OS. The OLE crossover design further complicates OS analysis. Whether PFS improvement translates to longer life in NETs, a disease with median survival measured in years, remains uncertain.

Stable disease at entry. Including patients with stable disease inflated the PFS endpoint. Critics note that some placebo patients who were "progressing" may have had slow-growing tumors that would have remained stable regardless. The trial design favored demonstrating a statistical difference but may overestimate the benefit in patients with truly progressive disease.

No comparison to observation. The placebo arm is not equivalent to "no treatment" since all patients underwent regular imaging. Whether lanreotide is better than watchful waiting with treatment at progression is a question CLARINET did not address.

The Bottom Line

Lanreotide is an FDA-approved somatostatin analog that reduces the risk of disease progression by 53% in patients with metastatic G1/G2 enteropancreatic neuroendocrine tumors (CLARINET trial: PFS 65.1% vs 33.0% at 24 months). Long-term data confirm sustained benefit beyond 96 weeks. No head-to-head comparison with octreotide exists, and guidelines treat both as equivalent first-line options. The evidence is limited to G1/G2, nonfunctioning, SSTR-positive tumors, and no overall survival benefit has been demonstrated.

Frequently Asked Questions

Lanreotide (Somatuline Depot) is FDA-approved for the treatment of unresectable, well-differentiated or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs). It is also approved for acromegaly (excess growth hormone production) and is under investigation for polycystic liver disease. Lanreotide is a long-acting somatostatin analog administered as a 120 mg deep subcutaneous injection every 28 days.

In the CLARINET trial of 204 patients with metastatic G1/G2 enteropancreatic NETs, lanreotide reduced the risk of disease progression by 53% compared to placebo (HR 0.47, P<0.001). At 24 months, 65.1% of lanreotide patients were progression-free vs 33.0% on placebo (Caplin et al., NEJM, 2014). The long-term extension showed median PFS of 32.8 months for continuous lanreotide users. No overall survival benefit has been demonstrated in randomized trials.

The most common side effects in the CLARINET trial were diarrhea (26%), abdominal pain (14%), and gallstones (10%). Gallstone formation is a class effect of all somatostatin analogs, caused by reduced gallbladder motility. Most gallstones were asymptomatic. Injection site reactions can occur. Lanreotide can also cause hyperglycemia or hypoglycemia by altering insulin and glucagon secretion. Quality of life scores were similar to placebo in CLARINET, indicating the drug is generally well-tolerated.

No head-to-head randomized trial has compared lanreotide to octreotide for antiproliferative efficacy in NETs. The CLARINET trial (lanreotide, HR 0.47) and PROMID trial (octreotide, HR 0.34) showed similar efficacy in different populations. Current ENETS, NCCN, and ESMO guidelines treat both as equivalent first-line options. The main practical difference is administration: lanreotide is self-injectable subcutaneously while octreotide LAR requires intramuscular injection by a healthcare provider.

Lanreotide is typically continued as long as the tumor remains controlled and the patient tolerates the drug. In the CLARINET open-label extension, patients received lanreotide for years beyond the initial 96-week trial with sustained benefit and consistent safety. Treatment is usually discontinued only upon disease progression, intolerable side effects, or transition to second-line therapy such as PRRT or everolimus. There is no established maximum duration of therapy.

Lanreotide primarily stabilizes tumor growth rather than shrinking tumors. In the CLARINET trial, objective tumor shrinkage (partial or complete response by RECIST criteria) was rare. The major benefit is disease stabilization: preventing tumors from growing rather than making them smaller. This "cytostatic" rather than "cytotoxic" mechanism is why PFS is the primary endpoint rather than tumor response rate. For patients seeking tumor shrinkage, PRRT or chemotherapy may be considered.